Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Evotec SENASDAQ: EVO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to -1.0%

Gross margin was -1.0% in Q1 FY2026, down 14.6 pp from a year earlier. On a trailing-twelve-month basis it was 11.4%, down 2.3 pp year over year. Over 3 fiscal years it narrowed by 14.9 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-1.0%-32.0 pp QoQ
Last fiscal yearDec 2025
8.3%-6.1 pp YoY
LTMMar 2026
11.4%-2.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-14.6 pp——
1 year-6.1 pp——
3 years-14.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
8.3%
Year-over-year change
-6.1pp

Gross Margin vs competitors

How EVO compares with its peers on the latest reported figures

  • EVO's LTM Mar 2026 gross margin of 11.4% is the lowest of the 10 companies compared; the peer median is 61.4%.
  • Its year-over-year change of -2.3 pp is the 7th highest of 9, against a peer median of -1.2 pp.
  • Over three fiscal years its change of -14.9 pp compares with a peer median of +6.4 pp.
EVO Competitors Peer median
Gross Margin for EVO and competitors
Company Period LTM level YoY 3-year change
PCRXPacira BioSciences, Inc.LTM Mar 202679.3% +1.7 pp+9.3 pp
NVCRNovoCure LimitedLTM Mar 202675.2% -2.0 pp-4.1 pp
HROWHarrow Health, Inc.LTM Mar 202674.1% -0.4 pp+3.7 pp
TDOCTeladoc Health, Inc.LTM Mar 202665.6% -4.9 pp+0.4 pp
ALVOAlvotechLTM Mar 202661.4% +0.8 pp+37.0 pp
SDGRSchrödinger, Inc.LTM Sep 202658.5% +0.4 pp-0.1 pp
SYRESpyre Therapeutics, Inc.LTM Sep 202650.0% ——
AZTAAzenta, Inc.LTM Sep 202644.2% -2.0 pp+9.2 pp
TLRYTilray Brands, Inc.LTM Feb 202627.7% -3.2 pp+10.7 pp
EVOEvotec SELTM Mar 202611.4% -2.3 pp-14.9 pp
PHVSPharvaris N.V.FY2025— ——
Peer median (excluding EVO) 61.4%-1.2 pp+6.4 pp

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue618.03M751.45M781.43M796.97M757.26M
Cost of Revenue466.49M577.38M606.38M682.09M694.6M
Gross Profit151.54M174.07M175.05M114.88M62.66M
Gross Margin24.5%23.2%22.4%14.4%8.3%
Research & Development65.7M76.64M68.53M50.86M74.33M
Selling, General & Admin105.45M156.19M169.61M188.2M123.65M
Operating Expenses110.55M153.22M222.56M257.4M197.97M
Depreciation & Amortization70.4M83.2M92.98M101.62M95.55M
EBITDA316.63M(57.61M)24.13M(80.66M)(13.89M)
EBITDA Margin51.2%-7.7%3.1%-10.1%-1.8%
Operating Income41M20.85M(47.51M)(142.52M)(135.31M)
Operating Margin6.6%2.8%-6.1%-17.9%-17.9%
Interest Income2.27M8.34M9.26M2.44M4.25M
Interest Expense9.25M13.15M11.74M11.7M13.87M
Other Income / Expenses195.98M(174.81M)(33.09M)(51.46M)12M
Income Before Tax236.98M(153.96M)(80.59M)(193.98M)(123.31M)
Pre-Tax Margin38.3%-20.5%-10.3%-24.3%-16.3%
Income Tax Expense21.47M21.7M3.32M2.1M(23.88M)
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Net Margin34.9%-23.4%-10.7%-24.6%-13.1%
EPS (Basic)0.65(0.49)(0.23)(0.56)(0.28)
EPS (Diluted)0.65(0.49)(0.23)(0.56)(0.28)
Weighted Avg Shares332.81M353.35M353.87M353.29M355.16M
Weighted Avg Shares (Diluted)332.81M353.41M353.87M354.59M355.16M

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.